A Phase 1, Randomized, Double-blind, Placebo-controlled, Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GT-1 in Healthy Adult Subjects
Not yet recruiting
Phase of Trial: Phase I
Latest Information Update: 17 Dec 2018
At a glance
- Drugs LCB10-0200 (Primary)
- Indications Gram-negative infections
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Geom Therapeutics
- 10 Dec 2018 Status changed from planning to not yet recruiting.
- 30 May 2018 According to a Geom Therapeutics media release, this trial is expected to begin in 2H of 2018.
- 30 May 2018 According to a Geom Therapeutics media release, company plans to submit an IND to the FDA in 2H 2018.